Compare Mattel Inc (MAT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Neurocrine Biosciences Inc — how do they compare? Mattel Inc trades at $14.8 (market cap $4.30B), while Neurocrine Biosciences Inc trades at $158.35 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.8× Mattel Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| MAT | NBIX | |
|---|---|---|
Market Cap | $4.30B | $16.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $185.50 |
52-Week Low | $13.05 | $123.10 |
Enterprise Value | $6.52B | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $14.74, down 0.34% today, with a bullish technical signal from moving averages and oversold RSI levels. Recent Q2 2026 earnings missed estimates despite 10% revenue growth, reflecting margin pressure from higher costs. The company maintains solid profitability with a 7.78% net margin and attractive valuation at a P/E of 11.22. Cash flow turned negative in 2025 due to increased financing outflows, though operations remain cash-generative.
Outlook is mixed: analyst consensus leans buy (53%) with a $14 price target, but rising expenses and toy market volatility pose risks. The stock's appeal hinges on execution of its entertainment-driven growth strategy and cost management amid economic headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
